Ñо¿ÐÔ°¢¶û´Äº£Ä¬²¡ÖÎÁÆLECANEMAB»ñµÃÃÀ¹úFDA¿ìËÙÉêÇëͨµÀÖ¸¶¨

ÈÕ±¾¶«¾©ºÍÃÀ¹úÂíÈøÖîÈûÖݽ£ÇÅÊÐ £¬2021Äê12ÔÂ24ÈÕ-ng28ÄϹ¬Öêʽ»áÉ磨×ܲ¿£º¶«¾© £¬CEO£ºÄÚÌÙÇç·ò £¬ÒÔϼò³Æ¡°ng28ÄϹ¬¡±£©ºÍ²³½¡¹«Ë¾£¨Nasdaq£ºBIIB £¬¹«Ë¾×ܲ¿£ºÂíÈøÖîÈûÖݽ£ÇÅÊÐ £¬CEO£ºMichel Vounatsos £¬ÒÔϼò³Æ¡°²³½¡¡±£©Ðû²¼ £¬lecanemab ÊÇÒ»ÖÖÓÃÓÚÖÎÁÆÔçÆÚ°¢¶û´Äº£Ä¬²¡(AD)µÄÑо¿ÐÔҩΦµí·ÛÑùÂѰף¨A¦Â£©Ô­ÏËά¿¹Ìå £¬ÒÑ»ñµÃÃÀ¹úʳƷҩƷ¼à¶½ÖÎÀí¾Ö (FDA)µÄ¿ìËÙÉêÇëͨµÀÖ¸¶¨¡£FDAÓÚ2021Äê6ÔÂÊÚÓèlecanemabÍ»ÆÆÐÔÁÆ·¨³Æºô¡£ Í»ÆÆÐÔÁÆ·¨³ÆºôºÍ¿ìËÙÉêÇëͨµÀÖ¸¶¨ÊÇFDAµÄÁ½¸ö¼Æ»® £¬Ö¼ÔÚÔö½øºÍ¼ÓËÙÐÂÒ©µÄ¿ª·¢ £¬ÒÔÂú×ãÄÇЩδ±»Âú×ãµÄÒ½ÁÆÐèÇóÖУ¨ÀýÈ磺°¢¶û´Äº£Ä¬²¡£©ÖÎÁÆÑÏÖØ»òΣ¼°ÉúÃüµÄ¼²²¡ £¬²¢ÌṩÓëFDAƵ·±»¥¶¯µÄʱ»ú¡£

2021Äê9Ô £¬ng28ÄϹ¬¿ªÊ¼Æ¾¾Ý¼ÓËÙÅú׼ͨµÀÏòFDAת¶¯Ìá½»lecanemabµÄÉúÎïÖÆ¼ÁÐí¿ÉÉêÇ루BLA£©¡£BLAÖ÷Òª»ùÓÚ2bÆÚÁÙ´²Ñо¿(Study 201)µÄÁÙ´²¡¢ÉúÎï±ê¼ÇÎïºÍÄþ¾²ÐÔÊý¾Ý £¬Õë¶ÔÔçÆÚADºÍÈ·ÕïµÄµí·ÛÑùÂѰײ¡ÀíѧºÍ°üÀ¨Èý²¿·Ö£¨·ÇÁÙ´²¡¢ÁÙ´²ºÍCMC£©µÄ·ÇÁÙ´²ºÍÁÙ´²ÉêÇëÒѾ­Ìá½»¡£lecanemab 2bÆÚÑо¿½á¹û±êÃ÷ £¬ÔÚ¶à¸öÁÙ´²ÖÕµãÖÐA¦Â°ß¿é¸ß¶È½µµÍ²¢ÇÒÁÙ´²Ï½µÁ¬Ðø¼õÉÙ¡£ÔÚÑо¿201ÖÐ £¬A¦Â°ß¿é¼õÉÙˮƽÓë¶ÔÁÙ´²ÖÕµãµÄÓ°ÏìÖ®¼äµÄÏà¹ØÐÔ½øÒ»²½Ö§³ÖA¦Â×÷ÎªÌæ´úÖյ㠣¬¿ÉÒÔºÏÀíµØÔ¤²âÁÙ´²»ñÒæ¡£

lecanemab Clarity ADÔçÆÚADµÄ3ÆÚÁÙ´²Ñо¿ÕýÔÚ½øÐÐÖÐ £¬²¢ÓÚ2021Äê3ÔÂÍê³ÉÁËÕÐļ £¬¹²ÓÐ1,795Ãû»¼Õß¡£FDAÒѾ­Í¬ÒâClarity ADµÄ½á¹ûÔÚÍê³Éºó¿ÉÒÔ×÷ΪÑéÖ¤Ñо¿À´ÑéÖ¤ lecanemabµÄÁÙ´²»ñÒæ¡£°üÀ¨À´×ÔClarity ADµÄÒþ±ÎÄþ¾²Êý¾ÝÒÔÖ§³ÖÕýÔÚ½øÐеÄת¶¯Ìá½»¡£ÁíÒ»ÏîIIIÆÚÁÙ´²Ñо¿AHEAD 3-45ÕýÔÚÆÀ¹ÀlecanemabÖÎÁÆÁÙ´²Ç°ADºÍµí·ÛÑùÂѰ×Éý¸ßµÄ¼ÓÈëÕßÒÔ¼°ÔçÆÚÁÙ´²Ç°ADºÍÖжȵí·ÛÑùÂѰ׵ļÓÈëÕßµÄÁÆÐ§¡£±ðµÄ £¬ng28ÄϹ¬»¹Æô¶¯ÁËlecanemabƤϸøÒ©µÄIÆÚÑо¿¡£

°¢¶û´Äº£Ä¬²¡ÊÇÒ»ÖÖÑÏÖØµÄ¡¢½øÐÐÐÔµÄºÍÆËÃðÐԵļ²²¡ £¬ÖÎÁÆÑ¡ÔñºÜÉÙ¡£ng28ÄϹ¬ºÍ²³½¡ÖÂÁ¦ÓÚΪÔçÆÚAD»¼Õß¡¢ËûÃǵļÒÈËºÍÆÚ´ýËûÃǵÄÒ½ÁÆ×¨ÒµÈËÊ¿´øÀ´ÐµÄÖÎÁÆÑ¡Ôñ¡£